supp.fit

Coenzyme Q10 and Omega-3 Fatty Acids: study protocols

9 study groups took Coenzyme Q10 together with Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.

Coenzyme Q10: what the research found →

Dose per serving from research: Coenzyme Q10

9 study groups in 9 studies say how much Coenzyme Q10 participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 100 mg to 250 mg, 78% of 9 study groups.

Daily doseStudy groups
25 mg to 50 mg
2
50 mg to 100 mg
0
100 mg to 250 mg
7

Dose per serving from research: Omega-3 Fatty Acids

9 study groups in 9 studies say how much Omega-3 Fatty Acids participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 2.5 g to 5 g, 78% of 9 study groups.

Daily doseStudy groups
500 mg or less
1
500 mg to 1 g
1
1 g to 2.5 g
0
2.5 g to 5 g
7

Commonly used together

2 of 9 study groups took Coenzyme Q10 and Omega-3 Fatty Acids with something else, but nothing that 3 or more different studies gave.

9 study groups

Study
The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial
2009 · both supplements · Nondiabetic patients with stage 3–4 chronic kidney disease
200 mg4 g8 weeks—
Women have higher levels of CoQ(10) than men when supplemented with a single dose of CoQ(10) with monoglycerides omega-3 or rice oil and followed for 48 h: a crossover randomised triple blind controlled study
2022 · CoQ10 + MAG-OM3 · Healthy men and women aged 18–50 years
200 mg1 g1 day30
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
2016 · n-3 fatty acids + CoQ · Men and women aged 25–75 years with chronic renal impairment (eGFR >15 and <60 mL/min/1.73 m²)
200 mg4 g8 weeks18
n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease
2015 · n-3 fatty acids and CoQ · Patients with chronic kidney disease
200 mg4 g8 weeks—
Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia
2017 · third group (statin + omega-3 PUFA + CoQ10) · People with combined dyslipidemia and elevated TAG levels; age and sex not reported
200 mg2.52 g90 days—
The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease
2018 · n-3 FA plus CoQ · Patients with chronic kidney disease (CKD)
200 mg4 g8 weeks—
The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial
2019 · Multinutrient supplementation group · Women aged 19–35 with polycystic ovary syndrome (PCOS)
30 mg500 mg90 days30
Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants
1997 · omega-3 FAs and antioxidants · male smokers with combined hyperlipidemia
30 mg5 g6 weeks—
A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease
2016 · n-3 fatty acids and Coenzyme Q10 · Patients with chronic kidney disease; age and sex not specified.
200 mg4 g8 weeks—
Coenzyme Q10 and Omega-3 Fatty Acids: study protocols | supp.fit